Alignment between global regulators can benefit sponsors and authorities alike by reducing duplication of effort and lowering the costs associated with drug reviews, but according to experts, there are a number of barriers that prevent convergence.
Key Takeaways
- While regulatory collaborations could benefit sponsors in the cell and gene sector, alignment is often hindered by practical barriers.
“I think we all agree with the principal benefit of convergence… but from a practical perspective, the simple fact is,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?